Suffolk Construction recently celebrated the topping-off ceremony for 585 Kendall, a mixed-use development in Kendall Square, Massachusetts.
The 16-storey building, designed by CBT Architects and developed by BioMed Realty, combines laboratory and office space with a performing arts centre.
Set to open in 2026, the project aims to serve the diverse needs of the Cambridge community.
The building will feature approximately 55,000 square metres of lab and office space leased by Takeda Pharmaceuticals for their Global R&D centre.
Additionally, it will house a 2,700-square-metre performing arts centre, including a 400-seat performance space, multipurpose rooms, and an indoor garden developed in partnership with Global Arts Live.
The development is pursuing LEED Gold certification or higher, emphasising sustainability through water and energy efficiency, 100 per cent renewable electricity, and enhanced ventilation strategies.
The design also incorporates biophilic principles to improve occupant wellbeing.
John Fish, Chairman and CEO of Suffolk, expressed pride in reaching this milestone, stating: “Building a sophisticated project in the heart of the innovation district of Cambridge requires vision, dedication, innovation and collaboration.”
He thanked BioMed Realty and Takeda for their partnership and investment in the community.
The 585 Kendall project is set to become a key component of the Canal District, reinforcing the neighbourhood’s reputation as a hub for science and the arts.
With its unique combination of research facilities and public spaces, the development aims to create a vibrant environment where science, art, and community converge.